Graft Versus Host Disease (GVHD) Market-Epidemiology Insights to 2023
©
Summary
Orbis Research delivers key insights on the Graft Versus Host Disease (GVHD) market in a new report titled “Graft Versus Host Disease (GVHD)-Epidemiology Insights to 2023”In this report, Orbis Research sheds light on the various factors and trends impacting market growth over the forecast period 2023
Description
“Graft Versus Host Disease (GVHD) -Epidemiology Insights -2023” Report provides an overview of the disease GVHD for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs) from 2013-2023.
GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD happens when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them. The disease is divided into two sub-types, acute GVHD which occurs usually in the initial 2-3 months after transplantation, and chronic GVHD that occurs after 3-4 months after transplantation and has more diverse complications. Although being used as a preventive therapy rather than treatment, Temcell-HS is currently the only therapy available for GVHD. It is marketed in Canada, Japan and Netherlands. According to, the total number of HSCTs and number of incident cases for first HSCTs is expected to grow at a CAGR of 2.80% and 2.90% respectively for the period 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Get a PDF Sample of Report at:
http://www.orbisresearch.com/contacts/request-sample/343497 .
Scope
-Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
-The Report covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
Some Key Points Of Report Are:
Graft Versus Host Disease (GVHD)
Disease Definition
Disease Types
Acute GvHD
Chronic GvHD
Grades of GvHD
Pathophysiology
Risk Factors for GVHD
Diagnosis
Epidemiology and Patient Population
Key Points
UNITED STATES
-Assumptions and Rationale
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
EUROPE
-Assumptions and Rationale
Germany
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
France
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
Spain
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
Italy
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
United Kingdom
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
JAPAN
-Assumptions and Rationale
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
Appendix
Report Methodology
Consulting Services
Disclaimer
Place a Purchase Order for this Report at:
http://www.orbisresearch.com/contact/purchase/343497 .
Orbis Research delivers key insights on the Graft Versus Host Disease (GVHD) market in a new report titled “Graft Versus Host Disease (GVHD)-Epidemiology Insights to 2023”In this report, Orbis Research sheds light on the various factors and trends impacting market growth over the forecast period 2023
Description
“Graft Versus Host Disease (GVHD) -Epidemiology Insights -2023” Report provides an overview of the disease GVHD for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs) from 2013-2023.
GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD happens when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them. The disease is divided into two sub-types, acute GVHD which occurs usually in the initial 2-3 months after transplantation, and chronic GVHD that occurs after 3-4 months after transplantation and has more diverse complications. Although being used as a preventive therapy rather than treatment, Temcell-HS is currently the only therapy available for GVHD. It is marketed in Canada, Japan and Netherlands. According to, the total number of HSCTs and number of incident cases for first HSCTs is expected to grow at a CAGR of 2.80% and 2.90% respectively for the period 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Get a PDF Sample of Report at:
http://www.orbisresearch.com/contacts/request-sample/343497 .
Scope
-Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
-The Report covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
Some Key Points Of Report Are:
Graft Versus Host Disease (GVHD)
Disease Definition
Disease Types
Acute GvHD
Chronic GvHD
Grades of GvHD
Pathophysiology
Risk Factors for GVHD
Diagnosis
Epidemiology and Patient Population
Key Points
UNITED STATES
-Assumptions and Rationale
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
EUROPE
-Assumptions and Rationale
Germany
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
France
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
Spain
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
Italy
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
United Kingdom
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
JAPAN
-Assumptions and Rationale
-Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan
-Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
-Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
Appendix
Report Methodology
Consulting Services
Disclaimer
Place a Purchase Order for this Report at:
http://www.orbisresearch.com/contact/purchase/343497 .